U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry EPIMERIC
Molecular Formula C6H8O6.C4H6N4O3
Molecular Weight 334.24
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALLANTOIN ASCORBATE

SMILES

C([C@@]([H])([C@]1([H])C(=C(C(=O)O1)O)O)O)O.C1(C(=NC(=N1)O)O)NC(=N)O

InChI

InChIKey=BMZVXYKKNCVBBF-RXSVEWSESA-N
InChI=1S/C6H8O6.C4H6N4O3/c7-1-2(8)5-3(9)4(10)6(11)12-5;5-3(10)6-1-2(9)8-4(11)7-1/h2,5,7-10H,1H2;1H,(H3,5,6,10)(H2,7,8,9,11)/t2-,5+;/m0./s1

HIDE SMILES / InChI
The aluminum salt of Allantoin, Alcloxa combines the astringent and anti-microbial properties of aluminum with the anti-irritant, soothing and healing properties of Allantoin. Alcloxa is particularly suited for use in anti-perspirants, acne treatments and foot care products. Alcloxa is a compound that combine the properties of aluminum salts with the properties of allantion. The allantion component ehhances the action of the aluminum salts and serves to overcome irritations experienced by many individuals who may be sensitive to the use of aluminum alts. The aluminum component reduces sweat by causing the sweat gland ducts swell. Alcloxa also add to the antiperspirant properties the deodorant effect because of its bacteriostatic action. It showed bacteriostatic properties at concentrations of 0.2% particularly against Gram + bectaria (B. subtilis, S. aureus, P. vulgaris, Pityrosporum ovale). This is ascribable to two different mechanisms: first bacterial growth is retarded due to a decrease in the amount of water present, second aluminum salt have itself an antimicrobial action. In baby products is indicated for its healing reparative action, in the treatment of diaper rash. Also is approved in haemorrhoidal product for its soothing and keratolytic action. In oral care products Alcloxa is useful for its astringent antibacterial properties. It is very indicated in formulations for sensitive teeth, periodontal and gum diseases (like gingivitis, irritable and bleeding gums). Use levels: 0.1-1%. − In antiacne products the slightly astringent effect promotes healing of pustules and acne lesions. It reduces the extension of infected skin eruptions, healing them and developing a soothing action. May be used alone or also in combinations with other antimicrobial agents in order to fight acne more effectively. Use levels: 0.5-2.0%.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
BODYGLIDE FOR HER

Approved Use

helps prevent and helps relieve chafed, chapped or cracked skin. helps protect from the drying effects of wind and cold weather. temporarily protects minor cuts, scrapes, burns.

Launch Date

1.25902075E12
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

protects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis.
Primary
Unknown

Approved Use

protects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis.
Primary
Unknown

Approved Use

protects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
6.43 μg/mL
10 mg/kg 3 times / day steady-state, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALLANTOIN plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
30 μg × h/mL
10 mg/kg 3 times / day steady-state, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALLANTOIN plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.69 h
10 mg/kg 3 times / day steady-state, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALLANTOIN plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
[Pharmacological study of dihydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate. I. Toxicity].
1962 Jul-Aug
[Evaluation of the anti-ulcer drugs using image analysis technology: effect of aldioxa containing preparation on the experimental gastric ulcer in rats].
1989 Nov
[The effect of aldioxa on the formation of gastritis induced with sodium hydroxide].
1990 Nov
[Acidified aspirin-induced gastric lesion in rats with hepatic cirrhosis produced by N-nitrosodiethylamine or carbon tetrachloride. Effect of aldioxa on gastric lesions].
1994 Mar
Aldioxa improves delayed gastric emptying and impaired gastric compliance, pathophysiologic mechanisms of functional dyspepsia.
2015 Dec 1

Sample Use Guides

In general, for adults, take 3 to 4 tablets (300 to 400 mg of the active ingredient) a day, in 3 to 4 divided doses.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
ALLANTOIN ASCORBATE
INCI  
INCI  
Official Name English
UREA, (2,5-DIOXO-4-IMIDAZOLIDINYL)-, COMPD. WITH L-ASCORBIC ACID (1:1)
Common Name English
ALLANTOIN-ASCORBIC ACID COMPOUND
Common Name English
ALLANTOIN ASCORBATE [INCI]
Common Name English
L-ASCORBIC ACID, COMPD. WITH N-(2,5-DIOXO-4-IMIDAZOLIDINYL)UREA (1:1)
Common Name English
Code System Code Type Description
PUBCHEM
67732897
Created by admin on Sat Jun 26 15:34:36 UTC 2021 , Edited by admin on Sat Jun 26 15:34:36 UTC 2021
PRIMARY
CAS
127941-88-2
Created by admin on Sat Jun 26 15:34:36 UTC 2021 , Edited by admin on Sat Jun 26 15:34:36 UTC 2021
NON-SPECIFIC STOICHIOMETRY
FDA UNII
76WX3J5GER
Created by admin on Sat Jun 26 15:34:36 UTC 2021 , Edited by admin on Sat Jun 26 15:34:36 UTC 2021
PRIMARY
CAS
57448-83-6
Created by admin on Sat Jun 26 15:34:36 UTC 2021 , Edited by admin on Sat Jun 26 15:34:36 UTC 2021
PRIMARY
ECHA (EC/EINECS)
260-739-1
Created by admin on Sat Jun 26 15:34:36 UTC 2021 , Edited by admin on Sat Jun 26 15:34:36 UTC 2021
PRIMARY